Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $18,802.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 632 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $18,802.00. Following the transaction, the senior vice president now directly owns 128,748 shares of the company's stock, valued at $3,830,253. This trade represents a 0.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Paula Green also recently made the following trade(s):

• On Monday, May 5th, Paula Green sold 1,101 shares of Twist Bioscience stock. The stock was sold at an average price of $37.65, for a total transaction of $41,452.65.
• On Wednesday, April 2nd, Paula Green sold 140 shares of Twist Bioscience stock. The stock was sold at an average price of $38.73, for a total value of $5,422.20.
• On Thursday, March 20th, Paula Green sold 291 shares of Twist Bioscience stock. The stock was sold at an average price of $41.68, for a total value of $12,128.88.
• On Thursday, March 6th, Paula Green sold 918 shares of Twist Bioscience stock. The shares were sold at an average price of $40.91, for a total value of $37,555.38.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded up $0.42 on Tuesday, hitting $28.68. 30,297 shares of the company were exchanged, compared to its average volume of 973,758. The stock's 50 day moving average price is $36.44 and its 200 day moving average price is $42.69. Twist Bioscience Co. has a 1-year low of $27.12 and a 1-year high of $60.90. The firm has a market capitalization of $1.72 billion, a P/E ratio of -8.47 and a beta of 2.54. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Hedge Funds Weigh In On Twist Bioscience

A number of large investors have recently bought and sold shares of TWST. Arizona State Retirement System boosted its holdings in Twist Bioscience by 1.3% in the fourth quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock worth $789,000 after purchasing an additional 219 shares during the period. Van ECK Associates Corp increased its stake in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after acquiring an additional 267 shares during the last quarter. Hillsdale Investment Management Inc. boosted its stake in shares of Twist Bioscience by 0.4% during the 4th quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock worth $3,625,000 after acquiring an additional 300 shares in the last quarter. GAMMA Investing LLC boosted its stake in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after purchasing an additional 303 shares during the period. Finally, Deerfield Management Company L.P. Series C grew its holdings in shares of Twist Bioscience by 1.7% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company's stock worth $1,107,000 after purchasing an additional 403 shares in the last quarter.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of analyst reports. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Guggenheim reiterated a "buy" rating and issued a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th. Robert W. Baird lowered their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. JPMorgan Chase & Co. reduced their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Finally, The Goldman Sachs Group cut their target price on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $50.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.